FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $40,000 | -32.2% | 680 | 0.0% | 0.01% | -28.6% |
| Q2 2021 | $59,000 | -6.3% | 680 | -10.9% | 0.01% | 0.0% |
| Q1 2021 | $63,000 | -22.2% | 763 | -14.7% | 0.01% | -22.2% |
| Q4 2020 | $81,000 | -36.2% | 894 | -84.3% | 0.01% | -52.6% |
| Q1 2020 | $127,000 | +9.5% | 5,700 | -4.2% | 0.02% | +35.7% |
| Q4 2019 | $116,000 | -48.7% | 5,950 | -59.0% | 0.01% | -41.7% |
| Q3 2019 | $226,000 | -23.4% | 14,525 | -0.1% | 0.02% | -22.6% |
| Q2 2019 | $295,000 | +16.1% | 14,535 | +0.5% | 0.03% | -48.3% |
| Q1 2019 | $254,000 | +30.9% | 14,462 | -4.4% | 0.06% | +27.7% |
| Q4 2018 | $194,000 | -31.7% | 15,127 | -13.2% | 0.05% | -16.1% |
| Q3 2018 | $284,000 | +94.5% | 17,434 | +35.2% | 0.06% | +93.1% |
| Q2 2018 | $146,000 | +147.5% | 12,899 | +113.7% | 0.03% | +141.7% |
| Q1 2018 | $59,000 | – | 6,036 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $34,095 | 9.92% |
| Redmile Group, LLC | 12,957,222 | $130,738,370 | 5.35% |
| GCM Grosvenor Holdings, LLC | 1,037,256 | $10,465,913 | 2.67% |
| Casdin Capital, LLC | 2,050,000 | $20,684,500 | 1.60% |
| DAFNA Capital Management LLC | 550,940 | $5,558,985 | 1.57% |
| Artal Group S.A. | 2,600,000 | $26,234 | 1.46% |
| Monaco Asset Management SAM | 250,000 | $2,522,500 | 0.76% |
| Parametrica Management Ltd | 32,254 | $325,443 | 0.67% |
| Boxer Capital, LLC | 1,250,000 | $12,612,500 | 0.66% |
| Bellevue Group AG | 4,861,279 | $49,050,305 | 0.65% |